Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study
Background: Targeted therapies have prolonged the survival of patients with metastatic renal cell carcinomas (RCC). However, the majority of patients with metastatic RCC develop treatment resistance and disease progression. The programmed cell death protein 1 inhibitors offer a new ray of hope for s...
Main Authors: | Waseem Abbas, Anjali Aggarwal, Promila Pankaj, Rachna Jain |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Cancer Research, Statistics, and Treatment |
Subjects: | |
Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2021;volume=4;issue=1;spage=55;epage=60;aulast=Abbas |
Similar Items
-
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
by: Haris Zahoor, et al.
Published: (2018-10-01) -
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020-02-01) -
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
by: Vadim S. Koshkin, et al.
Published: (2018-01-01) -
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
by: Go Noguchi, et al.
Published: (2018-04-01) -
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
by: Lisa B.E. Shields, et al.
Published: (2021-07-01)